8K filed today!
On January 14, 2013, Genesis Biopharma, Inc.’s (the “Company”) Chief Executive Officer Anthony J. Cataldo, with the consent of the Company’s Board of Directors, undertook a leave of absence from his position as the Company’s Principal Executive Officer without prejudice to his rights under his employment agreement. During the leave of absence, Mr. Cataldo will remain a director of the Company.
(c) On January 14, 2013, General (Ret.) Merrill A. McPeak, who has served as a member of the Company’s Board of Directors since July 2011 and is a member of the Company’s Compensation Committee, was appointed to serve as interim Chief Executive Officer.
General McPeak has agreed to serve in the position of Interim Chief Executive Officer without any compensation agreement or arrangement with the Company at this time.
I think we can all see where this is heading.
